Global Genomics Group (G3), a precision-medicine-based biopharmaceutical company announced its first precision diagnostic biomarker ‘knowPLAQUETM’ for the detection of atherosclerotic coronary artery disease.
"knowPLAQUETM" is a mass-spectrometry-based metabolomics diagnosis biomarker signature for the detection of atherosclerotic coronary artery disease, based on a simple mass spectrometry measurement from a standard blood draw.
It is the lead product in the company’s diagnostic biomarker portfolio. Generally, "knowPLAQUETM" is used to identify the patients who are affected with any plaque in their coronary arteries. It is the first diagnostic blood test that was specifically designed and developed to recognize plaque symptoms.
Atherosclerosis is the underlying malevolent abnormality responsible for coronary artery disease, which can result in heart attack, stroke and sudden cardiac death.
The test can be used to ‘rule out’ the presence of any plaque in the heart when patients present with chest pain in the outpatient setting.
Various unnecessary nuclear stress tests can be eliminated by positioning this test as a ‘gatekeeper’ to the current clinical evaluation paradigm. This could save approximately 46% in the costs associated with the evaluation of chest pain patients.
"knowPLAQUETM" was discovered and validated in Global Genomics Group's own GLOBAL (Genetic Loci and the Burden of Atherosclerotic Lesions; NCT01738828) clinical study. The test was developed and validated in a total of 1,096 subjects.
